Platform run 1 of architecture 5, as the author pasted it on 2026-11-08 (score not reported; the platform's determinism check returned the golden, runs/determinism_finding.md).

Response 1
Reviewed 115 resources· 26m
Recommendation. Run review A: antipsychotics in people aged 65 and over, from April 2027.
It is expected to avoid 24 serious harms per year, compared with 12 for runner-up review B, a gap of 12 harms per year. This meets the programme’s decision rule: choose the review with the greatest expected serious harm avoided.
Final answers. The annual estimates and paired chart are on page 1 of `medicines_safety_review_2027.pdf`, under “Expected annual benefit”:

* A, antipsychotics in people aged 65 and over: 240 patients off medicine, avoiding 24 serious harms per year.
* B, benzodiazepines and Z-drugs in people aged 65 and over: 280 patients off medicine, avoiding 12 serious harms per year.
* C, gabapentinoids taken with an opioid: 460 patients off medicine, avoiding 11 serious harms per year.

Patient forecasts are rounded to the nearest 10 and harms to whole numbers, after calculation. The chart places patients off medicine beside harms avoided, with clearly separated scales. Review A is recommended; review B is the runner-up.
Hospital medicine letters appear on page 3, under “Hospital medicine letters received”. Rates combine the two specified trusts and are per 1,000 patients registered at the start of each half-year:

* Clun Valley PCN: H1 46.8, from 1,945 letters; H2 43.3, from 1,808 letters.
* Severn Gorge PCN: H1 44.1, from 1,590 letters; H2 40.4, from 1,459 letters.
* Teme Valley PCN: H1 46.5, from 1,825 letters; H2 40.6, from 1,592 letters.
* Wrekinside Central PCN: H1 43.0, from 2,608 letters; H2 37.4, from 2,273 letters.
* Wrekinside North PCN: H1 43.6, from 1,899 letters; H2 41.7, from 1,827 letters.

H1 is January-June 2026; H2 is July-December 2026. The federation total is 18,826 letters.
Quarterly pharmacist consultation rates are in `pharmacist_consultations_2026.csv`, in `patient_consultations_per_1000_registered_patients`, and reproduced on page 3 of the paper. Each rate uses the published registered population on the quarter’s first day:

* Clun Valley PCN: Q1 13.4; Q2 13.8; Q3 13.8; Q4 13.9.
* Severn Gorge PCN: Q1 12.7; Q2 10.8; Q3 13.6; Q4 12.7.
* Teme Valley PCN: Q1 14.6; Q2 13.4; Q3 14.4; Q4 12.9.
* Wrekinside Central PCN: Q1 12.3; Q2 11.2; Q3 11.5; Q4 11.1.
* Wrekinside North PCN: Q1 13.2; Q2 12.1; Q3 12.4; Q4 11.8.

The CSV contains 20 network-quarter rows, with exact consultation counts, period-start registered populations, period dates and one-decimal rates. The annual total is 11,233 patient consultations.
Step-by-step process.

1. Established the governing definitions. Read `medicines_safety_programme_2027.pdf`, `deprescribing_review_protocols_2026.pdf` and `clun_valley_pilot_close_out_2026.pdf` from the supplied archive. These establish the review eligibility rules, six-month cessation endpoint, age-specific excess-harm rates, decision criterion and activity-reporting definitions. No external clinical estimates were substituted.
2. Built the eligible population. Joined `patient_registrations_2020-2026.parquet` to `member_practice_register_2026.csv`, treating registration starts as inclusive and ends as exclusive. The registration data contain 317,930 intervals, with no invalid or overlapping intervals. At 31 December 2026, there are 223,011 current registrations, including 180,908 in the 22 active practices outside Clun Valley. Every current registration maps to a practice and network; none has a recorded death by that date. Missing registration ends mean open intervals, and missing death dates do not imply death.
3. Applied the prescribing protocols. Used `prescribing_issues_2025-07_2026-12.parquet` and `problem_list_extract_2026-12-31.csv`. Of 287,970 unique prescribing issues, 100,868 fall in 1 July-31 December 2026. Both acute and repeat issues count. Class-specific issue thresholds, age limits and dated SNOMED exclusions reduce 743 age-and-medicine candidates to 612 eligible records for A, 1,268 to 1,239 for B, and 1,755 to 1,636 for C. The respective exclusions are 131, 29 and 119. There were no missing issue fields, future-dated diagnoses or exact duplicate records requiring removal. These exact audit counts appear on page 2; headline patient forecasts use the requested rounding.
4. Estimated cessation and annual benefit. Used `deprescribing_pilot_outcome_log_2026.csv`, containing 710 reviews and 700 checks. The complete-case cessation probabilities are 64/160, 69/300 and 67/240, displayed as 40.0%, 23.0% and 27.9%. All 700 recorded outcomes agree with independent reconstruction from prescribing issues. For each review, expected patients off equals eligible patients multiplied by its cessation probability. Expected annual harms avoided equals that probability multiplied by the sum of eligible patients’ age-specific annual excess-harm rates. Those risk sums are 60.339, 51.126 and 38.783. This direct calculation implements the programme specification without an unnecessary predictive model.
5. Reconciled consultations. Combined `clinical_system_pharmacist_activity_2026.csv`, `pharmacist_hub_appointments_2026.csv` and the `Register` sheet of `hub_group_session_register_2026.xlsx`. The reconciliation is 9,301 clinical records + 2,897 attended individual hub appointments - 1,165 overlapping records + 200 attended group participants = 11,233 consultations. Excluded 482 non-attended individual appointments and 34 group non-attenders. Replaced 25 group-session slots with their attending patients, while retaining 151 distinct same-day clinical follow-ups. Converted hub timestamps from UTC to Europe/London; no consultation changed calendar date. Every consultation matches exactly one event-day registration.
6. Reconciled hospital letters. Used `trust_medicine_letters_feed_2019-2026.csv`, `trust_hospital_number_lookup.csv` and `practice_document_workflow_2026.csv`. Collapsed 176,956 medicine-line records to 138,532 distinct trust/reference letters. Trust-specific hospital-number lookup resolved 7,446 missing letter-level patient identifiers, with no failed lookups or patient conflicts. Parsed ISO and UK dates separately. Matched intact references directly; after the teaching hospital’s October reference change, used trust, patient and receipt timing with one-to-one assignment. The 2026 numerator comprises 15,116 exact-reference receipts + 3,710 recovered receipts = 18,826 letters. Excluded 425 receipts first received in January 2027 and did not invent receipt dates for 12 unmatched letters dated in 2026.
7. Calculated denominators and rates. Used `registered_list_sizes_2026.csv`, summing practices within each network before dividing. All 364 practice-month list sizes reconcile exactly to registration intervals. Consultation denominators use 1 January, 1 April, 1 July and 1 October 2026; letter denominators use 1 January and 1 July 2026. Clun Valley remains included in activity reporting. No registration or denominator was imputed.
8. Inspected but rejected unsuitable substitutes. `repeat_medication_courses_2026-12-31.csv` contains 16,547 course summaries, but lifetime issue counts and current-status flags do not establish six-month protocol eligibility. `epact2_prescribing_summary_2025-26.xlsx` contains 672 aggregate prescribing rows, but items are not eligible patients or sustained cessations. `emergency_admissions_falls_65plus_2025-2026.csv` contains 40 network-quarter rows, but ecological falls-admission trends cannot identify one review’s effect or cover the specified serious-harm endpoint. Their roles and exclusions are documented on page 5.
9. Tested robustness and checked the artifacts. Wilson cessation intervals, propagated through fixed risk totals, give annual-harm intervals of 20-29 for A, 10-14 for B and 9-13 for C. Treating every missing check as no demonstrated cessation gives 23, 12 and 11, preserving A’s lead and the rounded gap of 12. Applying published age-specific cessation rates also preserves the ranking. Letter-link validation correctly classified 12,426 known medicine documents and 16,623 other documents, with no false positives or negatives; alternative receipt windows gave identical network totals. The PDF was rendered and inspected, and every CSV rate was recalculated successfully.

Assumptions and judgment calls.

* Pilot outcomes transfer to the target population. The primary calculation uses each review’s pooled complete-case cessation rate. This is a planning assumption, not a randomised causal estimate. The report’s intervals do not include uncertainty in excess-harm rates or transferability.
* Full programme coverage is assumed. The estimates follow the specified annual formula and assume every eligible patient is reviewed. They are not a phased monthly implementation forecast, and the six-month outcome window does not halve the annual harm rate.
* Pilot inconsistencies are disclosed rather than concealed. Ten missing review-specific checks concern eight people; five involve deaths later than day 183. Published age strata reconcile to year-end ages, while one checked A participant and 11 checked B participants were below 65 at review. Conservative missing-outcome and age-exclusion sensitivities retain A as the preferred review.
* Consultation identity requires reconciliation. Cross-system overlaps agreeing on patient, day, pharmacist and review type count once. Separately identified clinical follow-ups remain separate consultations.
* Letter identities are not all certain. Eighteen linked documents involving nine patients retain ambiguous individual letter identities, but complete one-to-one assignments retain the same receipt documents and network totals. “First receipt” means first observed receipt in the supplied workflow; earlier receipts outside the extract cannot be independently ruled out.

Alternatives rejected.

* Choose C because it stops more medicines: C takes 460 patients off medicine, but avoids 11 harms, against A’s 24. The programme prioritises serious harm avoided.
* Choose B: B is the runner-up at 12 harms avoided, leaving a 12-harm annual gap. Holding B’s cessation rate fixed, A would tie it only if A’s rate fell to 19.5%, compared with its observed 40.0%.
* Use the action recorded at review as the outcome: 53 patients recorded as stopped subsequently received another issue. Sustained six-month cessation is the specified endpoint.
* Count source rows, medicine lines or group slots: These would double-count consultations, confuse 24,021 medicine lines with 18,826 letters, or undercount attending group patients.
* Use exact letter references alone or attribute consultations at year end: Reference-only linkage misses 3,710 receipts. Year-end attribution would lose 249 consultations and move 64 to another network.

Files produced.

* `/home/agent/workspace/medicines_safety_review_2027.pdf`: five-page board paper containing the recommendation, paired impact chart, runner-up and gap, network activity tables, methods, sensitivity checks and source audit.
* `/home/agent/workspace/pharmacist_consultations_2026.csv`: network-quarter consultation counts, period-start denominators, one-decimal rates and the identical recommendation.

Temporary analysis scripts and preview images were removed.
Packages installed. Installed into `/tmp/opencode`: pandas, pyarrow, openpyxl, reportlab and PyMuPDF, plus dependencies numpy, et-xmlfile, python-dateutil, tzdata, Pillow, charset-normalizer, networkx, onnxruntime, PyYAML, pymupdf-layout, pymupdf4llm, psutil, tabulate, flatbuffers, packaging and protobuf.
